Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

MLA

Shah, Nirav N., et al. “Pirtobrutinib Monotherapy in Bruton Tyrosine Kinase Inhibitor-Intolerant Patients with B-Cell Malignancies: Results of the Phase I/II BRUIN Trial.” Haematologica, vol. 110, no. 1, Jan. 2025, pp. 92–102. EBSCOhost, https://doi.org/10.3324/haematol.2024.285754.

APA

Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, M. S., Patel, M. R., Flinn, I., Gerson, J. N., Ma, S., Coombs, C. C., Cheah, C. Y., … Brown, J. R. (2025). Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica, 110(1), 92–102. https://doi.org/10.3324/haematol.2024.285754

Chicago

Shah, Nirav N, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, William G Wierda, Chaitra S Ujjani, et al. 2025. “Pirtobrutinib Monotherapy in Bruton Tyrosine Kinase Inhibitor-Intolerant Patients with B-Cell Malignancies: Results of the Phase I/II BRUIN Trial.” Haematologica 110 (1): 92–102. doi:10.3324/haematol.2024.285754.